Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of azacitidine added to standard primary therapy in elderly patients with newly diagnosed AML
2008-004583-40Phase 2Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Jan 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by Universitätsklinikum Münster. Primary endpoint: Event-free survival. Started Jan 2009; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2008-004583-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004583-40.